Leadership
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
Recent moves in the industry include C-suite changes at Moderna, Valerio Therapeutics and Ocugen, plus IDEAYA Biosciences acquires chief commercial officer from Gilead Sciences.
The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.
The motive for the shocking murder of Brian Thompson in New York City was still unknown Wednesday afternoon.
CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.
While most drug development in the multiple sclerosis space has focused just on relapse prevention, Immunic’s dual-acting therapy vidofludimus calcium also offers a novel approach for neurodegeneration, its CEO Daniel Vitt tells Scrip.
Martin Makary’s ties to a compounder and telehealth company offering compounded GLP-1s may concern the drug industry and raise questions about his fundamental beliefs in the FDA’s role regulating drug manufacturing.
The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.
The US FDA’s Peter Marks told the Jefferies meeting that the agency’s scientific leadership will be protected, and said it wants to do more to help the sector accelerate innovation.
CEO Vas Narasimhan has highlighted the strong momentum from six new products plus the old favorites Entresto and Cosentyx, saying that there are over 30 high-value medicines in the pipeline that will drive continued mid-single digit sales growth beyond 2029.
Chris Boshoff has been with Pfizer more than 10 years and has led oncology R&D and the integration of Seagen. He will succeed Mikael Dolsten, who will depart after leading R&D for nearly 15 years.
But the expected nominee brings little experience running a large government organization or with the policy and budget challenges confronting Medicare and Medicaid.
Following Phase III safety and cash problems, Inventiva has its eye on lanifibranor becoming the second oral agent approved in NASH. Former Intercept CEO Mark Pruzanski is advising the effort.
Novo Nordisk India MD talks to Scrip about what to expect when Wegovy arrives in India and the local trajectory of Rybelsus. The Danish group also shared findings of a study around obesity.
Recent moves in the industry include C-suite changes at Coya Therapeutics, Kancera and Verrica Pharmaceuticals, which acquires chief financial officer from Aceragen.
Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.
Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.
CEO Albert Bourla said Starboard Value’s push for change at Pfizer is coming 15 months late as the company is already executing a five-point plan to cut costs and pivot on strategy.
Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting
Recent moves in the industry include changes at the top at enGene Holdings, which also acquires chief technology officer from Albireo Pharma.